Abstract

Despite almost 30 years of research, no effective vaccine has yet been developed against HIV-1. Probably such a vaccine would need to induce both an effective T cell and antibody response. Any vaccine component focused on inducing humoral immunity requires the HIV-1 envelope (Env) glycoprotein complex as it is the only viral protein exposed on the virion surface. HIV-1 has evolved several mechanisms to evade broadly reactive neutralizing antibodies. One such a mechanism involves variable loop domains, which are highly flexible structures that shield the underlying conserved epitopes. We hypothesized that removal of such loops would increase the exposure and immunogenicity of these conserved regions. Env variable loop deletion however often leads to protein misfolding and aggregation because hydrophobic patches becoming solvent accessible. We have therefore previously used virus evolution to acquire functional Env proteins lacking the V1V2 loop. We then expressed them in soluble (uncleaved) gp140 forms. Three mutants were found to perform optimally in terms of protein expression, stability, trimerization and folding. In this study, we characterized the immune responses to these antigens in rabbits. The V1V2 deletion mutant ΔV1V2.9.VK induced a prominent response directed to epitopes that are not fully available on the other Env proteins tested but that effectively bound and neutralized the ΔV1V2 Env virus. This Env variant also induced more efficient neutralization of the tier 1 virus SF162. The immune refocusing effect was lost after booster immunization with a full-length gp140 protein with intact V1V2 loops. Collectively, this result suggests that deletion of variable domains could alter the specificity of the humoral immune response, but did not result in broad neutralization of neutralization-resistant virus isolates.

Highlights

  • The need for an effective HIV-1 vaccine is undisputed, but the challenges in the development of such a vaccine are formidable

  • Neutralizing Antibody Responses We studied the sera for virus-neutralizing capacity against various tier 1 and tier 2 HIV-1 strains

  • In this study we investigated the immunogenicity of three DV1V2 deleted variants of the HIV-1 Env protein

Read more

Summary

Introduction

The need for an effective HIV-1 vaccine is undisputed, but the challenges in the development of such a vaccine are formidable. One vaccine candidate showed some degree of protection in the RV144 phase III trial [1], the mode of protection is not yet entirely clear and it is questionable whether the use of a vaccine with only 31% efficacy would have a significant effect on the epidemic [2]. Traditional antiviral vaccines typically consist of live-attenuated or inactivated virus as these are usually effective in achieving protection against subsequent infection. Live-attenuated SIV/HIV was shown to induce protection against infection, it is not considered safe for public use because of the risk of reversion of the vaccine strain to a pathogenic phenotype [3,4,5,6].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call